Actos (Pioglitazone) for Adults 65 and Older: Transition-to-Adult-Care Guide

Why Pioglitazone Requires Special Attention in Patients Over 65

Pioglitazone works by activating peroxisome proliferator-activated receptor gamma (PPAR-gamma), which improves insulin sensitivity in muscle, fat, and liver tissue. That mechanism is effective for lowering blood glucose, but it also drives sodium and water retention at the renal collecting duct. Older adults carry baseline risks, including reduced cardiac reserve, lower bone density, and higher prevalence of bladder disease, that amplify every one of those side effects.

The 2023 American Geriatrics Society (AGS) Beers Criteria explicitly lists pioglitazone and other thiazolidinediones as drugs to avoid in patients with heart failure, noting that fluid retention can worsen or precipitate decompensation. [1] Because heart failure prevalence reaches approximately 10 percent in adults over 70, that caution applies to a meaningful share of the geriatric population seen in primary care and endocrinology offices.

What "Transition to Adult Care" Means for This Drug

The phrase "transition to adult care" in the geriatric context covers two distinct scenarios. The first is when a patient who has been managed in a pediatric or young-adult diabetes program crosses into standard adult medicine, typically between ages 18 and 25. Pioglitazone is rarely initiated in that young cohort, so the handoff is mostly about reconciling an existing regimen.

The second, more clinically common scenario involves the internal transition that happens when a patient with longstanding type 2 diabetes crosses the age-65 threshold and their risk profile changes enough that every drug on their list deserves re-evaluation. Pioglitazone is often one of the drugs that requires the most scrutiny at that inflection point.

Both scenarios share a common requirement: a structured medication reconciliation that documents the indication, dose, duration of use, and current contraindications before prescribing continues.

Pharmacokinetic Changes That Matter at Age 65

Renal clearance declines roughly 1 percent per year after age 40. [2] Pioglitazone itself is hepatically metabolized (CYP2C8 and CYP3A4), so renal function does not directly limit its clearance. However, its active metabolites, M-III and M-IV, are renally excreted. In patients with eGFR below 45 mL/min/1.73 m2, metabolite accumulation may extend drug exposure beyond what phase III trials modeled.

Body composition also shifts with age. Reduced lean mass and increased visceral adiposity change the volume of distribution for lipophilic drugs, and pioglitazone is highly protein-bound (greater than 99 percent). Albumin levels drop in frail older adults, which can transiently raise free drug concentration and increase the likelihood of fluid retention or hypoglycemia when pioglitazone is combined with insulin or a sulfonylurea.

Dosing Pioglitazone in Patients 65 and Older

The FDA-approved label permits the same dose range for older adults as for younger patients (15 to 45 mg once daily), but clinical guidelines recommend starting at the lowest available dose and titrating no faster than every 8 to 12 weeks in this age group. [3]

Starting Dose and Titration Schedule

Begin at 15 mg once daily regardless of body weight. After 8 to 12 weeks, check fasting glucose, HbA1c, weight, and signs of edema before considering a move to 30 mg. Most older adults with type 2 diabetes achieve adequate glycemic control at 30 mg or less; the 45 mg dose should be reserved for patients without heart failure, significant edema, or osteoporosis.

The PROactive trial (N=5,238, mean age 61.8 years) showed that pioglitazone 45 mg daily reduced the composite of all-cause mortality, non-fatal myocardial infarction, and stroke by 16 percent versus placebo (hazard ratio 0.84, 95% CI 0.72 to 0.98, P<0.027) in patients with type 2 diabetes and established macrovascular disease. [4] The cardiovascular signal is one reason some cardiometabolic specialists retain pioglitazone for older patients with insulin resistance and prior coronary disease, provided heart failure is absent.

Drug Interactions Common in the Geriatric Polypharmacy Context

Older adults average four to five concurrent prescription medications. Several commonly prescribed drugs interact with pioglitazone through CYP2C8:

• Gemfibrozil (a CYP2C8 inhibitor) raises pioglitazone exposure roughly three-fold. The FDA label recommends limiting pioglitazone to 15 mg daily when gemfibrozil is co-prescribed. [3]
• Rifampin (a CYP2C8 and CYP3A4 inducer) reduces pioglitazone AUC by approximately 54 percent, potentially eliminating glycemic benefit.
• Insulin co-administration increases the risk of hypoglycemia and fluid retention; the FDA label warns that insulin dose reduction may be required when pioglitazone is added. [3]

Quarterly medication reconciliation at every care-transition visit should flag these combinations before they become clinical problems.

Key Safety Concerns in the 65-Plus Population

Heart Failure and Fluid Retention

Fluid retention is the most clinically consequential side effect of pioglitazone in older adults. In the PROactive trial, hospitalization for heart failure occurred in 5.7 percent of pioglitazone patients versus 4.1 percent of placebo patients (P<0.001). [4] That absolute difference of 1.6 percentage points translates to a number-needed-to-harm of about 63, which is meaningful in a population already burdened with hypertension and coronary disease.

The AGS Beers Criteria states: "Thiazolidinediones: avoid in individuals with heart failure." [1] The American Diabetes Association Standards of Care (2024) similarly advises against pioglitazone in patients with symptomatic heart failure. [5]

Practical monitoring: weigh the patient at every visit, ask about new dyspnea or leg swelling, and check for jugular venous distension in anyone who gains more than 2 to 3 kg within four weeks of a dose increase.

Bone Fracture Risk

Pioglitazone suppresses osteoblast differentiation through PPAR-gamma activation, reducing bone formation. A meta-analysis published in Diabetes Care (N=14,716 pooled) found a relative risk of fracture of 1.45 (95% CI 1.18 to 1.79) in patients on thiazolidinediones versus comparators, with the signal stronger in women. [6]

In the PROactive trial specifically, fractures were observed in 44 women on pioglitazone versus 23 on placebo, a near-doubling of fracture events. [4] Older women with existing osteopenia or osteoporosis should receive a DEXA scan before pioglitazone is continued past the age-65 transition, and co-prescribing a bisphosphonate may be appropriate if T-score falls below negative 2.0.

Bladder Cancer

Post-marketing data and a 10-year prospective cohort study published in the BMJ (N=145,806) found that cumulative pioglitazone use of more than 24 months was associated with a hazard ratio of 1.75 (95% CI 1.22 to 2.52) for bladder cancer versus never-use. [7] The FDA added a label warning in 2011 and requires that prescribers discuss this risk with patients. [3]

Bladder cancer incidence increases sharply with age, from roughly 20 per 100,000 at age 60 to more than 100 per 100,000 at age 80 in men. [8] That background-rate increase makes the relative risk from pioglitazone more consequential in older men specifically. Before continuing pioglitazone past the age-65 transition, ask about gross hematuria and obtain a urinalysis. Any unexplained hematuria should prompt urology referral before the drug is continued.

Hypoglycemia Risk in Combination Regimens

Pioglitazone as monotherapy does not cause hypoglycemia, because it does not stimulate insulin secretion. However, most older adults on pioglitazone are also taking metformin, a sulfonylurea, or insulin. The sulfonylurea combination is particularly risky in older adults because hypoglycemia in this age group is associated with falls, fractures, cardiac arrhythmias, and accelerated cognitive decline. [9]

If a patient 65 or older is on pioglitazone plus a sulfonylurea (such as glipizide or glimepiride) at the time of the care transition, consider whether the sulfonylurea dose can be reduced or whether a safer agent can replace it.

The Structured Transition-of-Care Checklist for Pioglitazone

A structured handoff reduces medication errors by approximately 66 percent in chronic disease management according to a 2019 Cochrane review of transition-of-care interventions (N=27 trials). [10] For patients 65 and older transferring to a new care team while on pioglitazone, the following framework applies.

Pre-Transfer Documentation

The outgoing clinician should provide:

1. Current pioglitazone dose and the date it was last titrated
2. Most recent HbA1c, fasting glucose, and weight trend over the prior 12 months
3. Most recent echocardiogram or documentation of cardiac function (NYHA class if applicable)
4. DEXA scan results if available
5. Urinalysis result within the prior 6 months, or documentation that hematuria has been evaluated
6. Complete medication list with doses, specifically flagging gemfibrozil, rifampin, insulin, or sulfonylureas
7. EGFR and hepatic function labs within the prior 3 months

At the First Adult-Care Visit (Age 65 Transition)

The receiving clinician should:

• Re-confirm the original indication. Pioglitazone should be used only for type 2 diabetes; using it off-label for NAFLD or NASH in older adults is not FDA-approved and carries the same side-effect profile. [3]
• Re-assess heart failure status. New onset of heart failure since the last dose adjustment is an absolute reason to discontinue.
• Re-assess bladder symptom history.
• Calculate the patient's 10-year fracture risk using FRAX (available at shef.ac.uk/FRAX), particularly for postmenopausal women.
• Review glycemic targets. The ADA and the American Geriatrics Society both recommend HbA1c targets of 7.5 to 8.0 percent (or even 8.0 to 8.5 percent in frail patients) rather than the tighter targets applied to younger adults, because hypoglycemia risk outweighs microvascular benefit in this cohort. [5]

Ongoing Monitoring Schedule After Transition

| Parameter | Frequency | |---|---| | Weight and edema assessment | Every office visit | | HbA1c | Every 3 months until stable, then every 6 months | | Liver function tests | Baseline only (unless symptoms arise) | | eGFR and metabolic panel | Every 6 to 12 months | | Urinalysis | Annually, or any time gross hematuria occurs | | DEXA scan | Baseline at age 65, then per USPSTF fracture guidelines | | Medication reconciliation | At every care transition and annually |

When to Discontinue Pioglitazone at or After Age 65

Discontinuation should be considered, and often initiated, when any of the following applies:

• New or worsening heart failure (NYHA Class II or higher)
• Weight gain greater than 4 to 5 kg attributable to fluid retention that does not respond to dose reduction
• New diagnosis of bladder cancer, or unexplained hematuria pending workup
• T-score below negative 2.5 in a postmenopausal woman or a man with additional fracture risk factors, unless alternative agents are unavailable
• eGFR decline below 30 mL/min/1.73 m2 (metabolite accumulation is poorly characterized below this threshold)
• HbA1c persistently above target despite 45 mg daily (indicating a need for a different drug class)

The 2024 ADA Standards of Care list SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) and GLP-1 receptor agonists (semaglutide, liraglutide) as preferred agents for patients with established cardiovascular disease or high cardiovascular risk, categories that overlap substantially with the geriatric population. [5] A switch to one of these drug classes at the age-65 transition may offer better cardiorenal protection with fewer geriatric-specific harms than continuing pioglitazone.

Tapering vs. Abrupt Discontinuation

Pioglitazone does not require a pharmacologic taper in the way that corticosteroids or beta-blockers do. However, stopping it abruptly in a patient whose glycemic control depends on it will raise blood glucose within two to four weeks. The outgoing clinician should either ensure a bridge therapy is in place or schedule a follow-up glucose check within three to four weeks of discontinuation.

Glycemic Efficacy Data Relevant to Older Adults

Pioglitazone reduces HbA1c by approximately 0.5 to 1.4 percent versus placebo, depending on baseline HbA1c, dose, and background therapy. A 2006 meta-analysis in the Annals of Internal Medicine (12 trials, N=3,490) found a mean HbA1c reduction of 1.0 percent (95% CI 0.8 to 1.3 percent) for pioglitazone versus placebo over 16 to 26 weeks. [11]

The drug also reduces fasting plasma glucose, lowers triglycerides by 10 to 20 percent, and raises HDL cholesterol by 4 to 9 percent. Those lipid effects are potentially beneficial in older adults with metabolic syndrome, provided the cardiac and fracture risks are acceptable for the individual patient.

One important nuance: the onset of pioglitazone's full glycemic effect is slow, typically 8 to 12 weeks. Clinicians who initiate or continue pioglitazone at a care transition should not escalate the dose prematurely because of an HbA1c that has not yet responded.

Special Populations Within the 65-Plus Age Group

Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)

Pioglitazone at 30 to 45 mg daily has shown histologic improvement in NAFLD in multiple randomized trials, including a landmark NEJM study (N=247) in which pioglitazone reduced liver inflammation scores significantly versus placebo (P<0.001). [12] Some older adults with type 2 diabetes and concurrent NAFLD may be candidates for dual benefit, but the hepatic indication is not FDA-approved, and the benefit-risk calculation in patients over 65 must weigh fracture and fluid retention risks against hepatic benefit individually.

Patients With Insulin Resistance and Polycystic Ovary Syndrome (PCOS) Transitioning Through Menopause

Women with PCOS often carry insulin resistance into their 60s and may have been managed with pioglitazone or metformin for years. As they transition through menopause, estrogen loss accelerates bone loss, making the fracture risk from pioglitazone additive to the menopausal fracture risk. A DEXA scan before continuing pioglitazone past menopause is a reasonable standard for this subgroup.

Frail Older Adults

Frailty, characterized by unintentional weight loss, low grip strength, exhaustion, slow walking speed, and low physical activity, alters the risk-benefit calculus significantly. Frail patients tolerate falls and fractures poorly, and fluid retention in a frail older adult may precipitate hospital admission more readily than in a strong peer. The prescribing decision in frail patients 65 and older should default to discontinuation of pioglitazone unless a compelling glycemic reason exists and safer alternatives have been exhausted.

Patient Communication at the Age-65 Care Transition

Older adults transitioning to a new care team often experience gaps in understanding their own medication list. A brief conversation at the transition visit should cover:

• Why pioglitazone is or is not being continued
• What warning signs to report immediately: new leg swelling, sudden weight gain of more than 2 kg in a week, blood in urine, or new shortness of breath
• How to take the medication (once daily, with or without food, at the same time each day)
• What the glycemic target is, and how to use home glucose monitoring if prescribed

Written instructions using plain language (sixth-grade reading level or below) improve medication adherence in older adults by a measurable margin. A 2014 study in the Journal of General Internal Medicine found that low health literacy was associated with a 34 percent higher rate of medication errors in patients 60 and older. [13]